The evolving role of immunotherapy in mesothelioma and metastatic NSCLC

Learning objectives:

• Discuss the changing role of immunotherapy in the management of metastatic non-small cell lung cancer (NSCLC)
• Assess the role of immunotherapy in the malignant pleural mesothelioma (MPM) patient pathway
• Determine the role of combining immunotherapies for individuals with NSCLC or MPM

This program was made possible through sponsorship support from Bristol Myers Squibb Canada Co.

Speakers:

Dr. Penelope Bradbury, MB, BCh, FRACP, MD (UK)

Dr. Penelope Bradbury is a staff medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada; Associate Professor, Department of Medicine, University of Toronto, Canada. After obtaining her medical degree from the University of Cardiff, UK and fellow of Royal Australasian College of Physicians, she undertook postgraduate fellowships at Princess Margaret Cancer Centre and the Canadian Cancer Trials Group, ON, Canada. Dr. Bradbury’s main research interest is in the field of clinical trials for thoracic cancer. Before joining the Princess Margaret Cancer Centre, she held the position of a senior investigator within the Canadian Cancer Trials Group for the thoracic and investigational new drugs program, during which time she held a Cancer Care Ontario Research Chair in Experimental Therapeutics. Dr. Bradbury is the current chair of the Canadian Cancer Trials Group Thoracic Disease Site Committee and is a prior recipient of the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award.

Solange Peters, MD, PhD

Solange Peters, MD, PhD, is full professor and chair of medical oncology as well as the thoracic malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Professor Peters is currently in charge of teaching and patient care in the area of thoracic malignancies in the department of oncology of Lausanne University, where she is building a translational program in collaboration with the Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute. Professor Peters’ main fields of interest are new biomarkers discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy.

Professor Peters’ current research projects are focused on multimodality stage III NSCLC treatment strategies, immunotherapy in limited small cell lung cancer and advanced NSCLC and thymic malignancies, ALK inhibitors, HER2 inhibitors, as well as innovative immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre, focused on phase I predictive biomarkers and thoracic malignancies immunotherapy, and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator and Foundation Council member of the European Thoracic Oncology Platform.

Professor Peters has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, associate editor of the Annals of Oncology and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably as editor of the ESMO lung cancer clinical practice guidelines. She is the past-Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2022. She was also a member of the IASLC board of directors, and vice president of the Swiss Group for Clinical Cancer Research lung group.

Note: The same material will be presented at each webinar in the series. Please select the time that best aligns with your schedule.